Panelist discusses how new all-oral combination regimens are transforming the treatment landscape by addressing unmet needs ...

After the announcement, Sequans' stock (SQNS) climbed over 43% in 24 hours, peaking at $1.81 pre-market. By contrast, Bitcoin ...

An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic ...

CAOS implements three options strategies to provide exposure to stocks and interest rates while expecting to benefit from a ...

One of the biggest reasons to buy DIVO instead of SCHD is because it is actively managed. This active management attempts to ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to ...

Let me share an investment approach that targets one of the biggest financial challenges: high taxes. In my work, I have encountered many individuals who struggle with the burden of excessive taxation ...

Mechanisms of Resistance The biggest challenges for the cancer immunotherapy field are to understand the complex resistance mechanisms and to develop effective combination strategies to overcome ...

A dad-of-two, diagnosed with "incurable" cancer, said he could soon have "no evidence" of the disease, less than a year after ...

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...